Immunotoxicology Specialty
Section Newsletter
President’s Message
2014-2015
Executive Committee
President
Dr. Danuta Herzyk
Vice President
Dr. Rafael Ponce
Vice President-Elect
Dr. Peyton Myers
Secretary-Treasurer
Dr. Haley Neff-LaFord
Past President
Dr. Gary Burleson

Senior Councilor
Dr. Jamie DeWitt
Junior Councilor
Dr. Cheryl Rockwell
Postdoc Representative
Dr. Ashwini Phadnis-Moghe
Student Representative
Aimee Hillegas

The ImTox SS Newsletter ispublished 3 times/year (Summer,
Fall, and Winter). If you would like toshare an item of interest withmembers of the ImTox SS, please
send it to the Communications
Committee Chair. All comments on,or suggestions to, the newsletter are
welcome.

Ashwini Phadnis-Moghephadnisa@msu.edu

December 2014

In the last issue of the Newsletter I noted that the
ITSS is approaching its 30th anniversary in 2015.
This milestone in the history of our specialty section
has inspired me to reach out to Dr. Jack Dean,
Founding President, Dr. Daniel Wierda, 11th
President and Dr. Kenneth Hastings, 21st President,
and ask if they would be willing to share theirthoughts and highlights from the ITSS history. I am
delighted to say that they responded enthusiasticallyto my request and wrote three articles for a miniseries entitled “History of the Immunotoxicology Dr. Danuta Herzyk
Specialty Section” that is published in this issue. I President, ImTox SS
2014-2015
would like to express my great appreciation to Jack,Dan and Ken for their contributions and hope that our“seasoned” members will enjoy the memories and our
young members will learn about key players and themain work areas covered by this specialty section
from its beginning to the present time. Enjoy thereading!

Danuta Herzyk,
President, ITSS (2014-2015)

President’s Message………….………...............…………….…….….1
Student Postdoctoral Report ………………………………....….…...2
Announcements................................................................................2
Program Committee Update…………..…………………………….....3Awards Committee Update…………………………………….……....4
New and Noteworthy.........................................................................5
History of ITSS Mini-series……………...…………...........................6
Early Years of Immunotoxicology....................................................6
The second decade of ITSS..............................................................7
The third decade of ITSS...................................................................8
Recent Immunotoxicology Publications……………………….…...10

1

Immunotoxicology Specialty Section

Student & Postdoctoral Report

As the end of the year approaches, I hope that you are all getting excited for the 54th annual SOT
meeting in San Diego, CA. Remember that there are many great opportunities for students andpostdocs to get involved, including creating a video for the YouTox challenge. Students and postdocs
are invited to submit a short video answering the question “Why did I become a toxicologist?” Cashprizes will be awarded, so get creative and have some fun! (Deadline is Jan 14; more information
available at http://toxicology.org/ai/spd/studentservices.asp).
At the 54th annual SOT meeting, immediately after the ITSS reception, members of the ITSS
Executive committee (on Tuesday, March 24, 2015) will be hosting a Networking/Mentor panel
discussion with students and postdocs. Be sure not to miss out on speaking with immunotoxicologists
from academia, industry, and the government!
Don’t forget, the deadline for award nominations is quickly approaching. Awards available to students
and postdoctoral ITSS members include Best Presentation by a Student, Best Presentation by a
Postdoctoral Trainee, and Best Paper of the Year. Many travel awards are also available through thespecialty section and through SOT; check out the websites for details and deadlines.
http://www.toxicology.org/ISOT/SS/imtox/Index.asp
Lastly, I’d like to remind everyone to make sure their SOT member information is current and correct
so you don’t miss email reminders of the numerous events and activities available to students andpostdocs! Upcoming events include Chat with an Expert, Poster Tours, and Student/Postdoc Mixers
at the annual SOT meeting. If you would like to get involved in planning these great events, or haveany comments/suggestions, please contact Aimee Hillegas (ahillegas@mail.usciences.edu) or
Ashwini Phadnis (phadnisa@msu.edu).

Announcements!
Immunotoxicology networking event for graduate students and postdoctoral researchers
Wish there was more time to network with immunotoxicologists?
Join us for the first ‘Immunotoxicology Networking Event’ where you canmeet a panel of immunotoxicologists from industry, academia, governmentand consulting firms. It is an opportunity not to be missed especially if you
are a graduate student or postdoc wondering about a future career in thisfield. This event will be held on March 24, 2015 following the ITSS
reception. More details of the event will follow soon. Please watch thisspace for more information in the next newsletter. Email reminders and alink for signing up will be sent to the graduate student and postdoctoral
members of the specialty section soon!

December 20142

Immunotoxicology Specialty Section

ITSS-sponsored sessions at the 2015 SOT Annual Meeting
The sessions submitted by our membership for consideration at the annual meeting were fantastic
and well received. Among 19 sessions that the ITSS sponsored for review by the program committee,
eight were ultimately accepted as sessions at the annual meeting. This reflects the general interest in
our discipline and the science we pursue, the broad interactions immunotoxicology has with otherareas of toxicology, and the high quality work conducted by our membership.
The sessions sponsored by the Immunotoxicology Specialty Section at next year’s meeting promise
to be extremely compelling and timely. Stay tuned as the final program develops for when thesesessions will be presented, but in the meantime I’m pleased to share the approved sessions, below.
Congratulations to those who had sessions accepted, and many thanks to all who submitted session
proposals! Your efforts in putting these session proposals together are highly appreciated andextremely valuable to our discipline and the broader community. In addition, I want to thank thosevolunteers who helped review these proposals as we put them forward for consideration by the SOTProgram Committee.
As we prepare for the year ahead, it is not too soon to begin thinking about important, high impact
areas of immunotoxicology research that should be discussed in 2016 – the clock for these session
proposals begins at the end of the annual meeting, with formal proposals due at the end of April,
2015! I’m looking forward to seeing you all in what promises to be a fascinating meeting.
All the best.
Rafael Ponce, Program Committee Chair
Workshop Session (Chairs)
Current Understanding of Immune-Mediated Adverse Drug Reactions (Arno Siraki, University ofAlberta and Alison Harrill, University of Arkansas)
Strengths and Weaknesses of Mouse Models in Studies of Immunological Effects of Drugs andChemicals (Courtney Sulentic, Wright State University and Bindu Nanduri, Mississippi State
University)
Continuing Education (Chairs)
The New World of Cancer Immunotherapy: Challenges in Bench to Bedside Translation(Rodney Prell, Genentech and Rafael Ponce, Amgen)
Skeletal System Endocrinology and Toxicology (Alan Hoberman and Susan Smith, Charles River
Laboratories)
Roundtable Session (Chairs)
Should Respiratory Sensitizers Be Listed As Substances of Very High Concern (SVHC) under
REACH? (Jon Hotchkiss, Dow Chemical Company and David Basketer, DABMEB Consultancy, Ltd.)
Symposium Session (Chairs)
Epigenetics, Developmental Programming, and Immune Function: Where Do We Go fromHere? (Berran Yucesoy, University of Cincinatti and Victor Johnson, Burleson ResearchTechnologies)
Immune Responses to Different Classes of Inhaled Particulates: Unique vs. Shared Responses
and Mechanisms (Andrij Holian, University of Montana and Seishiro Hirano, National Institute forEnvironmental Risk, Japan)
Immunostimulant Cancer Treatments: Toxicology Programs with an Autoimmmune “Twist”(Lauren Black, Charles River Laboratories and Helen Haggerty, Bristol-Myers Squibb)

December 20143

Immunotoxicology Specialty Section

Call for Nominations from the Awards Committee
Did you read an outstanding immunotoxicology paper this year? Read a presentation abstract that
was amazing? Work with someone who you think embodies excellence in the field of
immunotoxicology? If you answered yes to any of these questions, I urge you to nominate the author,
the presenter, or the colleague for an award from the Immunotoxicology Specialty Section.
Recognizing these important contributions of our Specialty Section’s students, postdoctoral scientists,and colleagues is one of the most important undertakings of our Specialty Section. Additionally,
acknowledging the excellence of the scientists within our Specialty Section helps to demonstrate how
our science furthers the mission of the SOT.
Please make it difficult for the Awards Committee to choose recipients for these awards. Pleasenominate a student, postdoctoral scientist, or colleague for one of the Immunotoxicology Specialty
Section Awards. You also may nominate yourself for one or more awards. Descriptions of awards,
Awards Committee contacts, and due dates are listed below. For a more detailed description of theawards and their nomination criteria, please visit the Immunotoxicology Specialty Section website (http://www.toxicology.org/ISOT/SS/imtox/deadlines.asp).
Jamie DeWitt, Awards Committee Chair
Vos Lifetime Career Achievement Award in Immunotoxicology
This award was named for the late Professor Jeff Vos and will be presented to a senior investigator
whose body of work represents an outstanding career in immunotoxicology. Please submit nominations
to Danuta Herzyk by January 16, 2015.
Outstanding Senior Immunotoxicologist Award
This award will be presented to a senior investigator with more than 10 years of experience sinceobtaining the highest degree and whose work has made significant contributions to the field of
immunotoxicology. Please submit nominations to Rafael Ponce by January 16, 2015.
Outstanding Young Immunotoxicologist Award
This award will be presented to a young investigator with 10 years of less of experience since obtaining
the highest degree and whose work has made significant contributions to the field of immunotoxicology.
Please submit nominations to Rafael Ponce by January 16, 2015.
Best Paper of the Year Award
Authors of the paper deemed to be the best paper in immunotoxicology will receive this award. The
paper must have been published between January 1 and December 31 of the previous calendar year
and the first publication date (paper or e-version) will be considered the publication date.
Immunotoxicology papers published in any peer-reviewed journal are acceptable. Please submit
nominations to Jamie DeWitt by January 16, 2015.
Best Presentation by a Postdoctoral Trainee Award
Postdoctoral trainees who are presenting (poster or platform) at the 2015 SOT Annual Meeting are
eligible for this award. Nominees are asked to submit a written version of an immunotoxicology
presentation to be made at the Annual Meeting and a letter of nomination from the trainee’s advisor.
Please submit materials to Jamie DeWitt by January 16, 2015.

December 2014

4

Immunotoxicology Specialty Section

Best Presentation by a Student Award
Students who are presenting (poster or platform) at the 2015 SOT Annual Meeting are eligible for thisaward. Nominees are asked to submit a written version of an immunotoxicology presentation to bemade at the Annual Meeting and a letter of nomination from the student’s advisor. Please submit
materials to Jamie DeWitt by January 16, 2015.
HESI Immunotoxicology Young Investigator Travel AwardILSI HESI sponsors this award to assist young investigators (< 5 years from completing a graduate
dissertation) in attending SOT and presenting their research. Both US and international investigators
are encouraged to apply. Please submit nominations to Danuta Herzyk by January 16, 2015.

NEW AND NOTEWORTHY
Dr. Rodney Dietert, Professor of Immunotoxicology at Cornell University College of Veterinary
Medicine appears in the recently-released documentary film, Microbirth (www.microbirth.com).
Filmed partly at Cornell University, the movie deals with the impact of the microbiome, birthdelivery mode, and immune development on later-life health risks. In October, the film won theGrand Prix at the 2014 Life Sciences Film Festival in Prague among 39 entries(http://www.lsff.cz/en).

SAVE THE DATE!
54th Annual Society of Toxicology Meeting
March 22-26, 2015
San Diego, California
Late Breaking Abstract Submission- January 12, 2015
Early Registration Deadline- January 31, 2015
Housing Reservation- February 19, 2015
Standard Registration Deadline- February 28, 2015

December 2014

5

Immunotoxicology Specialty Section

History of ITSS- Mini series
Immunotoxicology: The Early Years 1977-1995
Submitted by the Founding President of the ITSS – Dr. Jack Dean
It is important to understand how the interest in immunotoxicology developed and flourishedamong toxicologists within government regulatory agencies and the pharmaceutical, chemical andconsumer product industries. The earliest interest in immunology among toxicologists started with theobservation that certain environmental chemicals (e.g., dioxins, PCBs, some pesticides, etc.) appeared
to target the immune system and alter its function as was highlighted in an early publication by J. Vos(1977). In parallel, the discipline of immunopharmacology caught the interest of many in the 70’s,
including this author, as the search for new chemical entities (NCEs) possessing immunological activity
and therapeutic potential flourished. In many pharmaceutical companies, immunologically active NCEs
and cytokines became a development target for the treatment of cancer, viral diseases and immune
deficiencies.
During the 1980’s toxicologists in industry were confronted for the first time with the safety assessmentof protein therapeutics (e.g., monoclonal antibodies, IFNs, lymphokines, cytokines, etc.) and NCEs
possessing novel immune activity. Consequently, most of the scientists working in the developing
discipline of immunotoxicology during this period got their training in pharmacology, immunology or
immunopharmacology, and rarely toxicology.
Recognizing the importance of this emerging field, the Gordon Research Conference on Drug Safety inthe summer of 1978 devoted two days to immunotoxicology which represented the first symposia on
this topic.
Shortly thereafter, the first Workshop on Methods and Approaches for Assessing
Immunotoxicology was organized in Williamsburg, VA, and was attended by over 50 scientists andphysicians. The Williamsburg meeting was immediately followed by an NIH/NIEHS Consensus
Meeting in Research Triangle Park, NC, with the objective of defining specific research needs for this
newly emerging field of immunotoxicology. During 1979-1982, the National Institute of Environmental
Health Sciences/NIH directed a major study on the immunobiological and toxicological effects ofpolybrominated biphenyl contamination in Michigan farmers and chemical workers. This was one of
the earliest examples of environmental exposure to a potentially immunotoxic agent.
This followed in 1981 with NIEHS awarding contracts for the development and validation of method inrodents for immunotoxicology assessment. These contracts went to A. Munson, et al., at the Medical
College of Virginia and P. Thomas, et al. at The Illinois Institute of Technology.
The discipline of immunotoxicology soon captured the imagination of the International Program on
Chemical Safety (IPCS) of the World Health Organization (WHO) and the first WHO sponsoredinternational meeting was held in 1984. During this meeting a formal definition was developed.
By the mid- to late-80’s most major pharmaceutical companies began recruiting toxicologists or
immunologists trained in immunotoxicology and established small groups to monitor for inadvertentimmune side-effects of new drug candidates. In 1998 it was reported that there were 12
pharmaceutical companies with groups involved in the safety assessment of NCEs for immunotoxic
potential.

December 2014

6

Immunotoxicology Specialty SectionDuring this period most of the focus was an ongoing efforts to standardize and validate these methods
in rodents using a tiered or phased approach in addition to multiple ring studies.
The field of immunotoxicology has matured considerably since this early period when most of the focus
was on methods development and validation in rodents. The field was successfully natured by theSociety of Toxicology (USA) in 1985 with the formation of the Immunotoxicology Specialty Section with50 charter members and J. Dean as the founding President. ITSS became one of the largest specialty
sections within the SOT. This was followed in 1992 with the formation of the Immunotoxicology
Technical Committee by the Health and Environmental Scientists Institute (HESI).
J.G. Vos, in CRC Crit. Rev. Toxicol. 5:67-101, “Immune Suppression as related to toxicology”, 1977.

The second decade of ITSS (1995-2005)
Submitted by the 11th President of the ITSS- Dr. Daniel Wierda
I would characterize the decade from 1995-2005, in immunotoxicology terms, as the era of
immunotoxicity regulations. In 1996-1997, the FDA Center for Devices and Radiologic Health, as wellas the Office of Science and Technology, and the Office of Device Evaluation were working on guidance
documents for immunotoxicity testing. Dennis Hinton reported that his final draft of the Red Book II was
almost ready for publication. Ken Hastings and the FDA Center for Drug Evaluation and Research(CDER) began drafting an immunotoxicity guidance document while Joy Cavagnaro was leading FDA
Center for Biologics Evaluation and Research (CBER)’s efforts in writing the Guideline for Preclinical
Testing of Biotechnology Derived Pharmaceuticals. The Environmental Protection Agency (EPA) was
intent on promulgating the Federal, Insecticide, Fungicide and Rodenticide Act (FIFRA) Immunotoxicity
Testing Guideline in harmony with the Organization for Economic Co-operation and Development(OECD) which proposed that chemical pesticides should undergo immunotoxicity testing in rodents, andthese tests should include the sheep red blood cell (SRBC) assay, serum IgG levels and thymus
weights. On a similar front the EPA was working on test rules for analyzing air pollutants under theleadership of Vicki Dellarco and Mary Jean Selgrade. There were other regulatory initiatives underway
as well: The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM)
was developing criteria for utilizing the mouse local lymph node assay. It represented the 1st effort todetermine how a weight of evidence approach might be used in immunotoxicity screens. In 2000, theJapanese Ministry of Health and Welfare proposed immunotoxicology as a safety topic for International
Conference on Harmonization (ICH).

Other highlights of this decade: Bob Luebke organized an ITSS Methods Committee to promote thedevelopment, standardization, and validation of assays useful in the detection of immunologic
impairment following exposure to chemicals. Mitch Cohen and Judy Zelikoff were leading ITSS in thedevelopment and promotion of lectures and continuing education courses in immunotoxicity at the NYU
Environmental Immunotoxicology Department. Student Awards began in 1996 with George Shopp as
one of the 1st organizers. Mitch Cohen launched the ITSS’s first website along with a membershipdirectory. The book Immunotoxicology and Risk Assessment was authored by Dennis Flaherty andpublished in 1999. Judy Zelikoff and Peter Thomas edited a book entitled Immunotoxicity of Metals in1998 and the first edition of Jacques Descotes’ book An Introduction to Immunotoxicology followed ayear later. Jacques’ Summer School in Immunotoxicology symposium series, held in France each year,
was also in full swing.

December 20147

Immunotoxicology Specialty Section

The book Developmental Immunotoxicology edited by Steve Holladay was published in 2004. A
workshop on environmental agents and autoimmune diseases was hosted by the National Toxicology
Program (NTP) also that year. In 2003, the Northwest Immunotoxicology Conference was held at the
University of Montana to explore the effects of synthetic and natural chemicals on the immune
system.
Immunotoxicology hot topics during this decade reflected by publications and symposia, included
benzene, TCDD, formaldehyde, neuroimmunotoxicity, autoimmunity, allergy, respiratory and aquatic
toxicology. The immunotoxicology theme was also picking up interest among regional SOT meetings
as evidenced by an increase in presentations on immunotoxicity. There was a steady increase inimmunotoxicology publications related to asthma, allergy, and hypersensitivity, especially by Ian
Kimber and colleagues, and the beginning crescendo of cytokine/chemokine-related immunotoxicity
papers, as well as interest in the immunotoxicology of autism.
Although not comprehensive, I hope the above snap shot that I gleaned from the newsletter archivesof the ITSS portrays the sense of growth and action prevalent during this decade. Building on thedecade before, the immunotoxicological science of this decade grew a larger network of
immunotoxicologists who helped mature the science of immunotoxicology and carried that knowledge
forward to the next decade.

The third decade of ITSS (2005-present)
Submitted by the 21st President of the ITSS- Dr. Kenneth Hastings
Beginning in 2005, immunotoxicology was established as a mature science based on robust
methodologies and sound underlying principles. By this time, many co-operative studies had been
conducted and reported in peer-reviewed literature demonstrating intra- and inter- laboratory
concordance using standardized methods (such as what became known at this time as the Tdependent antibody response assay: TDAR), appropriate predictability for human health (the murine
local lymph node assay: LLNA), and validation of instrumental methods (such as flow cytometry) sothat these could take a place beside other long-used tools (such as automated blood cell counters).
What began as a long-term development and evaluation of methods was beginning to evolve into
efforts to use these data for what we now call translational science (or medicine).
Three important trends began to develop after 2005. The first was increased interest in in vitro
methods for immunotoxicology. The driving factors are more complex than generally appreciated.
Political pressure to reduce the use of animals is certainly an important issue driving some of these
efforts.
In November, 2003, a workshop on "The use of in vitro systems for evaluating
immunotoxicity" was held at the European Centre for The Validation of Alternative Methods (ECVAM),
in Ispra, Italy. This meeting was a harbinger of things to come – such as efforts that are underway
today to develop alternative methods (such as Tox21). But there were two other factors: tools wereneeded to develop biologic drugs where there were no adequate animal models (that is, lack ofpharmacologic activity to the test article). The extreme example of this was the TeGenero disaster inwhich nonclinical safety studies failed to adequately warn of serious adverse effects in humanvolunteers. Finally, we are beginning to observe adverse effects on immune function that may beadequately modeled in animals, but for which other tools (computational toxicology, in vitro assays)
may be at least as useful and may in fact be preferable for various reasons. Consider the issues of“anaphylactoid reactions” associated with both traditional as well as biologic drugs.
.
December 20148

Immunotoxicology Specialty Sectio

A second trend has been international outreach. Although SOT ITSS members had attended theJapanese Society of Immunotoxicology (JSIT) annual meeting in the past, at the 12th Annual Meetingin Tokyo in September, 2005, Mitch Cohen established with our colleagues there a standing
relationship that is still thriving. Along with our long established collaborations with European
members of SOT/ITSS, we assumed a more global presence.
Finally, the long-anticipated International Conference on Harmonization of Technical Requirements
for Registration of Human Medicines (ICH) Guidance on Immunotoxicology was promulgated as S8 in
the Spring of 2006 (actual date of adoption varies with the region). Although there is much to criticize
about the guidance/guideline, it was (and still is) the only regulatory document on immunotoxicologythat is applied internationally (yes, there are ISO, OECD, and WHO documents, but these do not havethe same regulatory standing as an ICH guidance). ICH S8 needs, to use ICH parlance,“maintenance”, but it remains a useful document.
What has been most surprising to me has been that immunotoxicology has become an important
issue in drug development. This may sound odd coming from someone who has a long career inpharmaceuticals, but my bias has always been that most drug-associated immunotoxic effects would
likely be predictable based on known pharmacology of the test article. This isn’t turning out to be true.
First: drug allergy is a persistent problem in drug development and we still lack adequate tools to
address this issue. Second: drugs intended to manipulate immune function (such as antiinflammatories) continue to surprise. I can remember when JC virus was considered an “orphan
virus”. We now know that it has pathogenic potential, unfortunately due to unanticipated drugassociated immunotoxicity. We now know that standard rodent carcinogenicity bioassays are
inadequate to detect known human carcinogens that have effects on immunity, and we now have amuch better understanding of why. Hopefully, this will lead to better methods for carcinogenicity
assessment of, for example, biologics. Finally, thanks in no small part to Mitch Cohen and the
Journal of Immunotoxicology, there is much more valuable cross-talk between immunotoxicologists
and others who have been conducting related research. I suspect environmental immunotoxicology
will remain the most important branch of the science, but we have experienced significant growth inmany related areas over the last ten years and this is likely to continue.

December 2014

9

Immunotoxicology Specialty Section

Recent Immunotoxicology Publications
Compiled by Haley Neff-LaFord. Anytime you have a new fully-published or electronically-available
article to report, please send the citation to Haley Neff-LaFord at hnlaford@seagen.com
Asthma, Allergy, Autoimmunity & Hypersensitivity
Basketter DA and Kimber I. Consideration of criteria for assignment of a (skin) sensitizer as a
substance of very high concern (SVHC) under the REACH regulation. Regul Toxicol Pharmacol 69:524528, 2014.
Blömeke B, Pot LM, Coenraads PJ, Hennen J, Kock M, and Goebel C. Cross-elicitation responses to 2methoxymethyl-p-phenylenediamine under hair dye use conditions in p-phenylenediamine-allergic
individuals. Br J Dermatol doi: 10.1111/bjd.13412, 2014.
Dearman RJ, Beresford L, McClain ES and Kimber I. Characterization of the allergenic potential ofproteins: an assessment of the kiwifruit allergen actinidin. J Appl Toxicol 34:489-497, 2014.
Eaton LH, Chularojanamontri L, Ali FR, Theodorakopoulou E, Dearman RJ, Kimber I and Griffiths CEM.
Guttate psoriasis is associated with an intermediate phenotype of impaired Langerhans cell migration.
Br J Dermatol 171:409-411, 2014.
Eaton LH, Roberts RA, Kimber I, Dearman RJ and Metryka A. Skin sensitization induced Langerhans
cell mobilization: variable requirements for tumour necrosis factor-α. Immunology 144:139-148, 2015.
Kimber I and Basketter DA. Categorization of protein respiratory allergens; the case of subilisin. Regul
Toxicol Pharmacol 68:488-492, 2014.
Kimber I, Basketter DA, Thyssen JP, Dearman RJ and McFadden JP. Chemical allergy in humans:
fresh perspectives. J Immunotoxicol 11:203-204, 2014.
Kimber I, Griffiths CEM, Basketter DA, McFadden JP and Dearman RJ. Epicutaneous exposure toproteins and skin immune function. Eur J Dermatol 24:10-14, 2014.
Kimber I and Pemberton MA. Assessment of the skin sensitizing potential of the lower alkyl
methacrylate esters. Regul Toxicol Pharmacol 70:24-36, 2014.
Lwin SM, Kimber I and McFadden JP. Acne, quorum sensing and danger. Clin Exp Dermatol 39:162167, 2014.
Maier A, Vincent MJ, Gadagbui B, Patterson J, Beckett W, Dalton P, Kimber I and Selgrade MJ.
Integrating asthma hazard characterization methods for consumer products. Regul Toxicol Pharmacol
70:37-45, 2014.
McFadden JP, Basketter DA, Dearman RJ, Puangpet P and Kimber I. The hapten-atopy hypothesis III:the potential role of airborne chemicals. Br J Hematol 170:45-51, 2014.
Nikitovic D, Berdiaki A, Galbiati V, Kavasi RM, Papale A, Tsatsakis A, Tzanakakis GN, and Corsini E.
Hyaluronan regulates chemical allergen-induced IL-18 production in human keratinocytes. Toxicol Lett
doi:10.1016/j.toxlet.2014.09.026., 2014.
Ratanji KD, Derrick JP, Dearman RJ and Kimber I. Immunogenicity of therapeutic proteins: influence of
aggregation. J Immuntoxicol 11:99-109, 2014.
Shaw FL, Mellody KT, Ogden S, Dearman RJ, Kimber I and Griffiths CEM. Treatment-related
restoration of Langerhans cell migration in psoriasis. J Invest Dermatol 134:268-271, 2014.

December 201410

Immunotoxicology Specialty Section

Recent Immunotoxicology Publications
Thyssen JP, McFadden JP and Kimber I. The multiple factors affecting the association between atopic
dermatitis and contact sensitization. Allergy 69:28-36, 2014.
Developmental Immunotoxicology
Miller VM, Bucher C, Zhu Y, McGuiness WM, Ryan LK, Siegel A and Zalcman S. Gestational flu
exposure induces neurochemical, hormonal, brainstem inflammatory changes and autism-likebehaviors in mice. Brain Behav Immun 33:153-163, 2013.
Viviani B, Boraso M, Valero M, Gardoni F, Marco EM, Llorente R, Corsini E, Galli CL, Di Luca M,
Marinovich M, López-Gallardo M, and Viveros MP. Early maternal deprivation immunologically primes
hippocampal synapses by redistributing interleukin-1 receptor type I in a sex dependent manner. Brain
Behav Immun doi: 10.1016/j.bbi.2013.09.008, 2013.

General Immunotoxicology
Andreoli C, Bassi A, Gregg EO, Nunziata A, Puntoni R, and Corsini E. Effects of cigarette smoking on
circulating leukocytes and plasma cytokines in monozygotic twins. Clin Chem Lab Med
doi:10.1515/cclm-2013-0290, 2014.
Jasten-Jolly J and Lawrence DA. Lead modulation of macrophages causes multiorgan detrimental
health effects. J Biochem Mol Toxicol 28:355-372, 2014.
Kuczma M, Kurczewska A and Kraj P. Modulation of bone morphogenic protein signaling in T cells forcancer immunotherapy. J Immunotoxicol 11:319-327, 2014.
Kulzer L, Rubner Y, Deloch L, Allgauer A, Frey B, Fietkau R, Dorrie J, Schaft N and Gaipl US. Normand hypo-fractionated radiotherapy is capable of activating human dendritic cells. J Immunotoxicol
11:328-336, 2014.
Lange A, Dlubek D, Zdziarski R, Chodorowska A, Mordak-Domagala M, Klimczak A, Lange J and
Jaskula E. Donor lymphocyte infusions to leukemic bone lesions are therapeutically effective in a Ph+
ALL patient with post-HSCT relapse. J Immunotoxicol 11:347-352, 2014.
Lopez MC, Palmer BE, and Lawrence DA. Naïve T cells, unconventional NK and NKT cells, and highly
responsive monocyte-derived macrophages characterize human cord blood. Immunobiol 291:756-765,
2014.
Luongo D, Russo R, Balestrieri A, Marzocco S, Bergamo P and Severino L. In vitro study of AFB1 andAFM1 effects on human lymphoblastoid Jurkat T-cell model. J Immunotoxicol 11:353-358, 2014.
Lynes MA, Hidalgo J, Manso Y, Devisscher L, Laukens D, and Lawrence DA. Metallothionein andstress combine to affect multiple organ systems. Cell Stress Chaperones 19:605-611, 2014.
Mendoza A, Torres-Hernandez JA, Ault JG, Pedersen-Lane JH, Gao D and Lawrence DA. Silica
nanoparticles induce oxidative stress and inflammation of human peripheral blood mononuclear cells.
Cell Stress Chaperones 19:777-790, 2014.
Metushi IG and Uetrecht J. Isoniazid-induced liver injury and immune response in mice. J
Immunotoxicol 11:383-392, 2014.

December 201411

Immunotoxicology Specialty Section

Recent Immunotoxicology Publications
Nishino R, Fukuyama T, Kosaka T, Hayashi K, Watanabe Y, Kurosawa Y, Ueda H and Harada T.
Effects of short-term oral combined exposure to environmental immunotoxic chemicals in mice. J
Immunotoxicol 11:359-366, 2014.
Rabe SZT, Mousavi SH, Tabasi N, Rastin M, Rabe SZT, Siadat Z and Mahmoudi M. Rose Bengal
suppresses gastric cancer cell proliferation via apoptosis and inhibits nitric oxide formation in
macrophages. J Immunotoxicol 11:367-375, 2014.
Silaeva YY, Grinenko TS, Vagida MS, Kalinina AA, Khromykh LM and Kazansky DB. Immune
selection of tumor cells in TCR β-chain transgenic mice. J Immunotoxicol 11:393-399, 2014.
Methods/Models
Balszuweit F, Menacher G, Bloemeke B, Schmidt A, Worek F, Thiermann H, and Steinritz D.
Development of a co-culture of keratinocytes and immune cells for in vitro investigation of cutaneous
sulfur mustard toxicity. Chem Biol Interact 223C:117-124, 2014.
Basketter DA, Gerberick GF and Kimber I. The local lymph node assay in 2014. Dermatitis 35:49-50,
2014.
Eaton LH, Roberts RA, Kimber I, Dearman RJ and Metryka A. The XS106 cell line: a Langerhans cellsurrogate with a selective type 2 phenotype. Immunology 144:139-148, 2015.
Mattei F, Schiavoni G, De Ninno A, Lucarini V, Sestili P, Sistigu A, Fragale A, Sanchez M, Spada M,
Gerardino A, Belardelli F, Businaro L and Gabriele L. A multidisciplinary study using in vivo tumor
models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune
cells. J Immunotoxicol 11:337-346, 2014.
Peachee VL, Smith MJ, Beck MJ, Stump DG and White KL Jr. Characterizatoin of the T-dependent
antibody response (TDAR) to keyhole limpet hemocyanin (KLH) in the Göttingen minipig. J
Immunotoxicol 11:383-392, 2014.
Ryan LK, Freeman KB, Masso-Silva JA, Aloyouny A, Markowitz K, Hise HG, Scott RW and Diamond
G. Activity of potent and selective host defense peptide mimetics in mouse models of oral candidiasis.
Antimicrob Agents Chemother 58:3820-3827, 2014.
Reviews/Books/Commentaries
Jewett A, Man Y, Cacalano N, Kos J and Tseng HC. Natural killer cells as effectors of selection anddifferentiation of stem cells; Role in resolution of inflammation. J Immunotoxicol 11:297-307, 2014.
Rollinski J and Hus I. Breaking immunotolerance of tumors: A new perspective for dendritic celltherapy. J Immunotoxicol 11:311-318, 2014.
Ryan LK. Vanadium pentoxide effects on the lung. In: Uversky V, Kretsinger RH and Permyakov EA(ed.). Encyclopedia of Metalloproteins. Springer, NY, NY; pp. 2324-2330, 2013.
Seliger B. The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor
genes, and transcription factors. J Immunotoxicol 11:308-310, 2014.

December 201412

Immunotoxicology Specialty Section